How is the "voluntary withdrawal" of certain licenses in 2026 reshaping the regulatory landscape for live-attenuated vaccines?
The early weeks of 2026 have introduced unexpected volatility to the chikungunya vaccine market following the voluntary withdrawal of certain biologics license applications (BLA) in the United States. While initially approved for travelers, new investigations into foreign "Serious Adverse Events" (SAEs) have led some major developers to pause their U.S. operations to conduct deeper safety...
0 Reacties 0 aandelen 547 Views 0 voorbeeld